(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

C ongress just passed a sweeping bill that includes changes to Medicaid expected to cut millions of people with low incomes ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

The results expose a striking prevalence of high-risk sexual behaviours. Over one-third of participants (34.0%) disclosed ...

In the mid-nineties, a friend of mine told me that he lost 30 friends and acquaintances to HIV/AIDS in just one week. It was a miracle that he was still alive. Although cases have decreased ...

President John Dramani Mahama has called for a youth-led national conversation on HIV prevention as the country faces a concerning surge in new infections, particularly among young people.

Prosper Okonkwo is the founding CEO of APIN-Public Health Initiatives, a leading Nigerian NGO that emerged from Harvard T.H.